The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | MPNs at ASCO 2022: cytopenic myelofibrosis, non-JAK inhibitor approaches & combination therapy
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, provides an overview of key takeaways in myeloproliferative neoplasms (MPNs) from the American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting cytopenic myelofibrosis as an area of unmet need in the field of MPNs. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
